Safety And Pharmacology Study Of SNX-5422 Mesylate In Subjects With Refractory Solid Tumor Malignancies
- Registration Number
- NCT00506805
- Lead Sponsor
- Esanex Inc.
- Brief Summary
Hsp90 is a chemical in the body that is involved in promotion of cancer. SNX-5422 is an experimental drug that blocks Hsp90. It is being evaluated for safety and efficacy in patients with cancer.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 44
Inclusion Criteria
- >18 years old
- histologically confirmed solid tumor malignancy
- refractory to available therapy or for which no therapy is available
- adequate organ function
Exclusion Criteria
- CNS malignancy
- significant GI disease
- at risk for prolonged QT interval
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Single Arm SNX-5422 -
- Primary Outcome Measures
Name Time Method adverse events and other safety assessments continuous
- Secondary Outcome Measures
Name Time Method tumor response measured by X-rays or scans after every 2 cycles
Trial Locations
- Locations (1)
Pfizer Investigational Site
🇺🇸Nashville, Tennessee, United States